Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Combatting disruptive ‘noise’ in quantum communication
In a significant milestone for quantum communication technology, an experiment has demonstrated how networks can be leveraged to combat disruptive ‘noise’ in quantum communications. The international effort led by researchers…
Stretchable quantum dot display
Intrinsically stretchable quantum dot-based light-emitting diodes achieved record-breaking performance. A team of South Korean scientists led by Professor KIM Dae-Hyeong of the Center for Nanoparticle Research within the Institute for…
Internet can achieve quantum speed with light saved as sound
Researchers at the University of Copenhagen’s Niels Bohr Institute have developed a new way to create quantum memory: A small drum can store data sent with light in its sonic…
